Who Paid My Doc
Mark Ritter
Sports Medicine Carmel, IN Medical Doctor
NPI 1770585911 CMS profile 352599
10767 Illinois St Ste 3000, Carmel, IN 46032
General payments
$13,498
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mark Ritter of Carmel, IN is reported in the CMS Open Payments database as having received $13,498 across 63 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 62nd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $25 | 1 | |
| 2024 | General | $750 | 1 | |
| 2023 | General | $2,284 | 2 | |
| 2022 | General | $320 | 4 | |
| 2021 | General | $3,349 | 29 | |
| 2020 | General | $1,725 | 11 | |
| 2019 | General | $5,045 | 15 |
Beside peers
- Mark Ritter
- Sports Medicine median
- Middle half of Sports Medicine
- National median
In program year 2025, general payments to Mark Ritter were reported at $25. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.
Show as a table
| Year | Mark Ritter | Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,045 | $1,176 | $199–$4,249 | $163 |
| 2020 | $1,725 | $708 | $96–$2,890 | $114 |
| 2021 | $3,349 | $1,213 | $152–$3,994 | $132 |
| 2022 | $320 | $1,230 | $159–$3,998 | $149 |
| 2023 | $2,284 | $584 | $146–$2,836 | $160 |
| 2024 | $750 | $628 | $163–$3,168 | $164 |
| 2025 | $25 | $664 | $172–$3,055 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 26 billing codesPaid by Medicare
$15,311
Medicare patients
49
Services billed
239
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 73% | |
| High blood pressure | 49% | |
| Ischemic heart disease | 22% | |
| Depression | 22% | |
| Chronic kidney disease | 0% | |
| Alzheimer's or dementia | 0% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 11 | 96 | $74 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
63 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sports Medicine in Indiana
Related records
Sports Medicine in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.